First Methylation Assay for Prostate Cancer Introduced by LabCorp
OncoMethylome's gene methylation technology used to advance the diagnosis of prostate cancer
When utilized in combination with conventional histopathology testing, an assay that detects the methylation status of key genes such as GST-Pi may provide for a more sensitive and accurate detection of prostate cancer than histology alone. The assay is anticipated to be useful for biopsies with suspicious histopathology, in cases where additional prognostic information is needed, and for patients who have elevated prostate specific antigen (PSA) values with biopsy findings that are repeatedly negative.
According to the company, this is the first commercially available molecular diagnostic test that incorporates OncoMethylome's patented methylation technology. Following numerous published clinical studies demonstrating the value of the GST-Pi methylation marker in prostate cancer, OncoMethylome licensed the prostate cancer applications to Veridex LLC, a Johnson & Johnson company, who subsequently issued a sublicense to LabCorp. Under the terms of the Veridex sublicense agreement, OncoMethylome will receive royalties and milestone payments.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.